LUAD is characterized by a high frequency of tumor‐driving mutations in gene for epidermal growth factor receptor (EGFR) (10–30%) or KRAS (20–40%) (da Cunha Santos et al., 2011). This evidence concerns the gene EGFR and neoplasm.